Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

521 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Schmitz C, Rekowski J, Müller SP, Hertenstein B, Franzius C, Ganser A, Bengel FM, Kroschinsky F, Kotzerke J, La Rosée P, Freesmeyer M, Hoeffkes HG, Hertel A, Behringer D, Mesters R, Weckesser M, Mahlmann S, Haberkorn U, Martens U, Prange-Krex G, Brenner W, Giagounidis A, Moeller R, Runde V, Sandmann M, Hautzel H, Wilop S, Krohn T, Dürk H, Heike M, Alashkar F, Brinkmann M, Trenn G, Wacker D, Kreisel-Büstgens C, Bernhard H, Heil G, Larisch R, Kurch L, Jöckel KH, Hoelzer D, Klapper W, Boellaard R, Dührsen U, Hüttmann A. Schmitz C, et al. Among authors: klapper w. Hematol Oncol. 2020 Aug;38(3):244-256. doi: 10.1002/hon.2697. Epub 2020 Feb 18. Hematol Oncol. 2020. PMID: 32067259
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Böttcher S, Asnafi V, Plonquet A, Siebert R, Callet-Bauchu E, Andersen N, van Dongen JJ, Klapper W, Berger F, Ribrag V, van Hoof AL, Trneny M, Walewski J, Dreger P, Unterhalt M, Hiddemann W, Kneba M, Kluin-Nelemans HC, Hermine O, Macintyre E, Dreyling M. Pott C, et al. Among authors: klapper w. Blood. 2010 Apr 22;115(16):3215-23. doi: 10.1182/blood-2009-06-230250. Epub 2009 Dec 23. Blood. 2010. PMID: 20032498 Free PMC article. Clinical Trial.
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial Investigators. Dührsen U, et al. Among authors: klapper w. J Clin Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11. J Clin Oncol. 2018. PMID: 29750632 Clinical Trial.
Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
Kurch L, Hasenclever D, Kluge R, Georgi T, Tchavdarova L, Golombeck M, Sabri O, Eggert A, Brenner W, Sykora KW, Bengel FM, Rossig C, Körholz D, Schäfers M, Feuchtinger T, Bartenstein P, Ammann RA, Krause T, Urban C, Aigner R, Gattenlöhner S, Klapper W, Mauz-Körholz C. Kurch L, et al. Among authors: klapper w. Pediatr Blood Cancer. 2019 Mar;66(3):e27539. doi: 10.1002/pbc.27539. Epub 2018 Nov 14. Pediatr Blood Cancer. 2019. PMID: 30426671
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U. Hüttmann A, et al. Among authors: klapper w. Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4. Ann Hematol. 2019. PMID: 30610279 Clinical Trial.
Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome.
Richter J, Hüttmann A, Rekowski J, Schmitz C, Gärtner S, Rosenwald A, Hansmann ML, Hartmann S, Möller P, Wacker HH, Feller A, Thorns C, Müller S, Dührsen U, Klapper W. Richter J, et al. Among authors: klapper w. Blood Cancer J. 2019 Aug 19;9(9):67. doi: 10.1038/s41408-019-0230-8. Blood Cancer J. 2019. PMID: 31427567 Free PMC article. No abstract available.
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, Sasse S, Sökler M, Kerkhoff A, Mathas S, Hüttmann A, Bormann M, Zimmermann A, Mettler J, Fuchs M, von Tresckow B, Baues C, Rosenwald A, Klapper W, Kobe C, Borchmann P, Engert A. Bröckelmann PJ, et al. Among authors: klapper w. JAMA Oncol. 2020 Jun 1;6(6):872-880. doi: 10.1001/jamaoncol.2020.0750. JAMA Oncol. 2020. PMID: 32352505 Free PMC article. Clinical Trial.
First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
Pouyiourou M, Meyer A, Stroux A, Viardot A, La Rosée P, Maschmeyer G, Kämpfe D, Kahl C, Vucinic V, Monecke A, Hirt C, Weber T, Meissner J, Witzens-Harig M, Böttcher S, Schmalenberg H, Marks R, Prange-Krex G, Kroschinsky F, Hauf E, Keller U, Koch K, Klapper W, Herold M, Scholz CW; East German Study Group for Hematology and Oncology (OSHO). Pouyiourou M, et al. Among authors: klapper w. Ann Hematol. 2020 Dec;99(12):2821-2829. doi: 10.1007/s00277-020-04171-7. Epub 2020 Jul 30. Ann Hematol. 2020. PMID: 32734548
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.
Hirt C, Hoster E, Unterhalt M, Hänel M, Prange-Krex G, Forstpointner R, Florschütz A, Graeven U, Frickhofen N, Wulf G, Lengfelder E, Lerchenmüller C, Schlag R, Dierlamm J, Fischer von Weikersthal L, Ahmed A, Harich HD, Rosenwald A, Klapper W, Dreyling M, Hiddemann W, Herold M. Hirt C, et al. Among authors: klapper w. Hemasphere. 2021 Jun 23;5(7):e600. doi: 10.1097/HS9.0000000000000600. eCollection 2021 Jul. Hemasphere. 2021. PMID: 34179697 Free PMC article.
521 results